Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BNR · Nasdaq · United States · Services-Medical Laboratories
In shortBurning Rock Biotech Ltd is loss-making, burns cash and holds more cash than debt, with revenue growing (+4.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -10.2% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -10.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -9.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -8.1% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.99× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -11.46 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -6.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 9.8% | 75/100 |
| Operating margin volatility | 67.3% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -1.4% | 9/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
CNY millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 508 | 563 | 537 | 516 | 540 |
| Cost of revenue | 144 | 183 | 174 | 153 | 137 |
| Gross profit | 364 | 380 | 363 | 362 | 403 |
| Research & development | 368 | 422 | 347 | 232 | 166 |
| Operating income | (797) | (980) | (669) | (358) | (55) |
| Interest expense | 1.5 | – | – | – | – |
| Pre-tax income | (796) | (969) | (651) | (341) | (54) |
| Income tax | 0.9 | 2 | 2.4 | 5.9 | 1.6 |
| Net income | (797) | (971) | (654) | (347) | (55) |
| Diluted EPS | ¥0.00 | – | – | – | – |
| Diluted shares (millions) | 0 | – | – | – | – |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
−11.46 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 28, 2026